… Objective/Rationale:              The orphan nuclear receptor Nurr1 plays a critical role in the development and … of midbrain dopamine neurons. Recent research also shows that it protects midbrain dopamine neurons from … effects. In support of our project, we identified three compounds with an identical chemical scaffold that activate …

… stimulation (DBS) targets malfunctioning brain circuits. Commonly used to treat Parkinson’s disease (PD), this surgical therapy can … stimulation settings have been selected (i.e., programmed). However, DBS programming often requires multiple clinic …

… of specific proteins, such as alpha-synuclein which forms toxic clumps in Parkinson's brains. However, the ability of ASOs to travel from the blood into … the brain alpha-synuclein protein, to find the most active combination for development as a new therapy. It could also …

… (FDA) last week that the federal agency refused to file the company's New Drug Application for inhaled … to treat "off" episodes in Parkinson's disease. When a company is ready for the FDA to review its drug for approval …

… Study Rationale: To study the pathogenic processes underlying Parkinson’s … PD, those that carry PD mutations but do not yet show signs of disease and those who have PD for which the … cases and GBA mutation carriers with and without PD, accompanied by major sets of clinical data, bio-banked plasma …

… Derek Shavell from Boca Raton, FL, is preparing for his Bar Mitzvah next year with a … few months by running, biking, walking and hiking. He will complete his mileage at the end of July by hiking the Grand … We checked in with Derek to find out why he chose to support Parkinson’s research as his Mitzvah Project.  Team …